Everest Medicines (1952) Status Update summary

Commercial and Financial Overview

• Achieved strong revenue base with commercial assets in nephrology, immunology, and infectious disease, targeting peak sales of 10 billion RMB ($1.5 billion) and nearing corporate profitability.

• mRNA vaccine pipeline positioned as a future organic growth driver, supplementing existing commercial portfolio.

mRNA Platform and Technology Advancements

• Developed a fully integrated, clinically validated mRNA platform with proprietary AI-driven antigen design and LNP delivery systems, ensuring robust production and enhanced T cell immunity.

• AI-driven mRNA sequence design optimizes codon usage and RNA structure, improving stability and protein expression up to fivefold over first-gen; proprietary lipid library enhances immunogenicity and enables tissue/cell-specific delivery.

• LNPs can be targeted to specific immune cells, improving efficacy and reducing off-target effects; validated in preclinical models.

• Self-owned GMP manufacturing facility supports end-to-end capabilities.

Pipeline Progress and Clinical Milestones

• EVM16, a personalized cancer vaccine, began an investigator-initiated trial in China with first patient dosed on March 4, 2025; phase I study underway.

• Off-the-shelf TAA cancer vaccine (EVM14) completed IND-enabling studies; US IND submitted in February 2025, China IND in progress.

• In vivo CAR-T program completed a non-human primate study and is progressing toward preclinical candidate selection.